5:13 PM
 | 
Mar 27, 2013
 |  BC Extra  |  Company News

Pozen submits combined NDA for PA32540, PA8140

Pozen Inc. (NASDAQ:POZN) submitted a combined NDA to FDA for PA32540 and PA8140 for the secondary prevention of cardiovascular disease...

Read the full 94 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >